Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database

Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecd...

Full description

Bibliographic Details
Main Authors: Stefania Chiappini, Fabrizio Schifano, John Martin Corkery, Amira Guirguis
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Brain Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-3425/10/2/105
id doaj-ab24c8229fdd47c0b2703bc800c56771
record_format Article
spelling doaj-ab24c8229fdd47c0b2703bc800c567712020-11-25T01:40:00ZengMDPI AGBrain Sciences2076-34252020-02-0110210510.3390/brainsci10020105brainsci10020105Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance DatabaseStefania Chiappini0Fabrizio Schifano1John Martin Corkery2Amira Guirguis3Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, UKPsychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, UKPsychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, UKSwansea University Medical School, Institute of Life Sciences 2, Swansea University, Singleton Park, Swansea SA2 8PP, UKBackground: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecdotally described. Aims: the 2005−2018 European Medicines Agency (EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible clozapine withdrawal- and misuse-/abuse-/dependence-related issues. Method: A descriptive analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related (13.3%) ADRs. A small number of overdose- and suicide-related ADRs were reported as well. Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake instances were reported in association with a history of substance abuse. Conclusions: Previous suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here supported, but further studies are needed. However, the misuse/abuse cases here identified might be difficult to interpret, given the lack of studies highlighting the possible recreational use of clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported here may, however, be a reason for concern.https://www.mdpi.com/2076-3425/10/2/105clozapineadverse drug reactionsmisusewithdrawaldependenceoverdose
collection DOAJ
language English
format Article
sources DOAJ
author Stefania Chiappini
Fabrizio Schifano
John Martin Corkery
Amira Guirguis
spellingShingle Stefania Chiappini
Fabrizio Schifano
John Martin Corkery
Amira Guirguis
Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
Brain Sciences
clozapine
adverse drug reactions
misuse
withdrawal
dependence
overdose
author_facet Stefania Chiappini
Fabrizio Schifano
John Martin Corkery
Amira Guirguis
author_sort Stefania Chiappini
title Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
title_short Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
title_full Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
title_fullStr Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
title_full_unstemmed Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
title_sort focus on clozapine withdrawal- and misuse-related cases as reported to the european medicines agency (ema) pharmacovigilance database
publisher MDPI AG
series Brain Sciences
issn 2076-3425
publishDate 2020-02-01
description Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecdotally described. Aims: the 2005−2018 European Medicines Agency (EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible clozapine withdrawal- and misuse-/abuse-/dependence-related issues. Method: A descriptive analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related (13.3%) ADRs. A small number of overdose- and suicide-related ADRs were reported as well. Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake instances were reported in association with a history of substance abuse. Conclusions: Previous suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here supported, but further studies are needed. However, the misuse/abuse cases here identified might be difficult to interpret, given the lack of studies highlighting the possible recreational use of clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported here may, however, be a reason for concern.
topic clozapine
adverse drug reactions
misuse
withdrawal
dependence
overdose
url https://www.mdpi.com/2076-3425/10/2/105
work_keys_str_mv AT stefaniachiappini focusonclozapinewithdrawalandmisuserelatedcasesasreportedtotheeuropeanmedicinesagencyemapharmacovigilancedatabase
AT fabrizioschifano focusonclozapinewithdrawalandmisuserelatedcasesasreportedtotheeuropeanmedicinesagencyemapharmacovigilancedatabase
AT johnmartincorkery focusonclozapinewithdrawalandmisuserelatedcasesasreportedtotheeuropeanmedicinesagencyemapharmacovigilancedatabase
AT amiraguirguis focusonclozapinewithdrawalandmisuserelatedcasesasreportedtotheeuropeanmedicinesagencyemapharmacovigilancedatabase
_version_ 1725047804999499776